---
title: "AbbVie Submits Rinvoq For FDA, EMA Approval In Non-Segmental Vitiligo"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274667977.md"
description: "AbbVie has submitted applications to the FDA and EMA for approval of Rinvoq to treat non-segmental vitiligo in adults and adolescents. The submissions are based on Phase 3 Viti-Up studies, which demonstrated significant improvements in skin repigmentation. Rinvoq is already approved for various immune-mediated inflammatory diseases. AbbVie shares rose 1.18% to close at $225.64 on Monday."
datetime: "2026-02-03T13:54:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274667977.md)
  - [en](https://longbridge.com/en/news/274667977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274667977.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274667977.md) | [English](https://longbridge.com/en/news/274667977.md)


# AbbVie Submits Rinvoq For FDA, EMA Approval In Non-Segmental Vitiligo

Add  as your preferred news source on Google

 Add Now

AbbVie (ABBV) on Tuesday said it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of Rinvoq for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV).

The submissions are based on data from the Phase 3 Viti-Up studies, which showed that upadacitinib met the co-primary endpoints of at least 50% improvement in total body repigmentation and at least 75% improvement in facial repigmentation from baseline at week 48.

Rinvoq is a prescription medicine approved for a range of immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis among others.

AbbVie shares closed at $225.64 on Monday, up 1.18%.

For comments and feedback contact: editorial@rttnews.com

Business News

### 相關股票

- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Abbvie (ABBV.US)](https://longbridge.com/zh-HK/quote/ABBV.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)

## 相關資訊與研究

- [Teva receives FDA approval for Prolia biosimilar](https://longbridge.com/zh-HK/news/281172040.md)
- [What You Need to Know Ahead of AbbVie’s Earnings Release](https://longbridge.com/zh-HK/news/281471479.md)
- [FDA approves new high dose Spinraza regimen for SMA](https://longbridge.com/zh-HK/news/281376767.md)
- [AbbVie Dermatology Data Highlights Immunology Depth And Emerging Skin Disease Opportunities](https://longbridge.com/zh-HK/news/280880145.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-HK/news/281346305.md)